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Abstract
We have previously shown that human plasma atrial K-natriuretic peptide (K-hANP) sequestering is a protective
phenomenon against amyloid aggregation. In the present work, the possible role of lipoproteins as K-hANP binding factors
has been investigated in vitro using an experimental model, developed in our laboratory, that allows to work at physiological
concentrations. This approach consists of gel filtration on Sephacryl S-300 HR of big K-[125I]hANP generated in phosphate
buffered saline or in human normal plasma supplemented or not with lipoproteins. The results of these experiments indicate
that high density lipoproteins (HDL) are responsible for the ANP binding phenomenon observed in vitro, while low density
lipoproteins and very low density lipoproteins do not directly interact with ANP. Moreover, the HDL remodeling process
occurring in vitro has been analyzed during plasma incubation by monitoring the redistribution of lipids and apolipoproteins
among the HDL subclasses. The changes in HDL size and composition observed in incubated plasma were compared with
the redistribution of endogenous and labeled big ANP. The obtained results revealed that both tend to follow the molecular
rearrangement in plasma of apolipoprotein A-I containing particles and suggested that, among HDL species, the small
particles are mainly involved in the ANP binding phenomenon. This hypothesis was further demonstrated by ligand blotting
experiments that confirmed the existence of differences in the ability of HDL particles to bind K-[125I]hANP. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Isolated atrial amyloid (IAA) is a relatively com-
mon disease in the aging human heart [1^3] and at-
rial K-natriuretic peptide (K-ANP) is the major im-
munoreactive subunit of amyloid ¢brils [4^6].
Analogously to other amyloid endocrine forms, it is
unclear why some peptide hormones give rise to
amyloid ¢brils. It is known that peptide aggregation
and ¢bril formation are greatly in£uenced by peptide
concentration, pH, oxidation, ionic strength and
temperature, as well as by the presence of amino
acid substitutions [7^13]. Indeed, a relationship be-
tween certain cardiac disorders, associated to high
ANP plasma levels, and the incidence and the degree
of IAA has been described [1,3].
Although it is not known whether ANP aggregates
in biological £uids, the circulating peptide exists as
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either a monomeric or macromolecular form at pico-
gram physiological concentration [14,15]. In a pre-
vious work [16] we investigated the nature of high
molecular weight (big) forms of ANP by setting up
an in vitro model suitable for studying the aggrega-
tion process of radiolabeled ANP at physiological
concentrations. We showed that the process is anal-
ogous to that occurring for other amyloidogenic pep-
tides [17^21]. In the presence of a preformed nucleus
(seed), the aggregation is suddenly initiated, follow-
ing a ¢rst order kinetic model, while in the absence
of seed, a lag time, longer than 8 days, is observed at
picogram ANP levels [16]. Such an in vitro study also
suggested that a part of the big ANP is the expres-
sion of binding to some plasma components and that
this binding competes with the ANP aggregation
process. Moreover, we con¢rmed previously reported
results [22], i.e., that the plasma binding factors are
not speci¢c carriers for ANP since the binding is not
saturable or reversible, thus acquiring the peculiarity
of a sequestration phenomenon. Hence, these ANP
binding factors may have an important role in im-
pairing amyloid formation and growth. In fact it is
probable that only the ANP not bound to proteins
can take part in the polymerization process generat-
ing amyloid ¢brils, as hypothesized for the amyloid
L-peptide (AL) responsible for amyloidosis associated
to Alzheimer’s disease [23,24].
Most of the information on sequestering factors
comes from studies on AL. Several circulatory pro-
teins, such as apolipoprotein (apo) E, apo J, apo A-I,
apo A-II and gelsolin, have been shown to bind and
form complexes with AL [24^30]. A recent study sug-
gests that the interaction of transthyretin (TTR) with
high density lipoproteins (HDL) occurs via associa-
tion with apo A-I [31]. To date, no information exists
about the interaction of such endogenous factors and
ANP. However, our previous ¢ndings [16] demon-
strate that human albumin did not bind monomeric
labeled ANP. These data are in line with some recent
reports [26,28], which demonstrate the inability of
albumin to bind monomeric AL. On the other
hand, the ubiquitous presence of some of the apoli-
poproteins in chemically diverse cerebral and sys-
temic amyloid deposits [32^36], together with the
demonstrated binding to soluble AL, give impetus
to the idea that these compounds may be designated
to sequester several amyloidogenic peptides in vivo.
On the basis of these observations, in the present
work we applied our previously presented experimen-
tal model [16] to test the e¡ect of HDL, low density
lipoproteins (LDL) and very low density lipoproteins
(VLDL) on the chromatographic distribution of
exogenous labeled ANP when incubated in bu¡er
and in human plasma at physiological concentration
(picograms). To further investigate the relationship
between lipoprotein and K-[125I]hANP, ligand blot-
ting experiments were carried out.
2. Materials and methods
2.1. Materials
All chemicals used were reagent grade and ultra-
pure water (Milli Q System Millipore, USA) was al-
ways used. K-[125I]hANP (speci¢c activity 2000 Ci/
mmol) and the K-hANP radioimmunoassay (RIA)
kit were obtained from Eiken Chemical (Japan).
Dextran (molecular mass 65^85 kDa), activated
charcoal (100^400 mesh), bovine serum albumin
(BSA) and lipoproteins isolated from human plasma
(HDL, LDL, VLDL) were obtained from Sigma
(Italy). Gel ¢ltration calibration kits and the HiPrep
Sephacryl S-300 High Resolution (HR) gel ¢ltra-
tion column, Kodak X-Omat AR ¢lm, intensifying
screens and hypercassette autoradiography were sup-
plied by Amersham Pharmacia Biotech (Italy). Im-
munodi¡usion plates and standards for apo A-I and
apo A-II assay were obtained from Daiichi Pure
Chemicals (Japan). Enzymatic kits for total choles-
terol and triglycerides were from Menarini Diagnos-
tics (Italy). The phospholipid assay kit was from Di-
acron (Italy). Visking dialysis tubing (MWCO 12
kDa) were supplied by Tecnochimica Moderna
(Italy). A human pooled plasma sample was ob-
tained from 20 healthy volunteers with their in-
formed consent. EDTA and aprotinin (500 kIU/ml
of blood) were used. The same pooled plasma, stored
at 370‡C in multiple aliquots, was used for all sub-
sequent analyses.
2.2. Ligand binding of K-[125I]hANP to lipoprotein in
solution
Big ANP was obtained by incubating 100 Wl of
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plasma or phosphate bu¡ered saline (PBS; 0.15 M
NaCl, 0.05 M Na-phosphate and NaN3 (0.02%, w/v),
pH 7.0) with 100 Wl of K-[125I]hANP (10 000^50 000
cpm) at 37‡C in a water bath for 24 h, as previously
reported [16]. In parallel experiments, physiological
amounts of HDL (230 Wg), LDL (230 Wg) and VLDL
(60 Wg) were added to 100 Wl of plasma or PBS. The
monomeric and big K-[125I]hANP were separated
by adding a dextran-coated charcoal (DCC) suspen-
sion (K-[125I]hANP/DCC, 1:10 v/v). The charcoal-
adsorbed K-[125I]hANP was pelleted by centrifuga-
tion at 1000Ug for 15 min at 4‡C and the super-
natant containing big K-[125I]hANP was counted in
a Q-counter. This separation method and its e⁄ciency
have been reported previously [16,22]. The big K-
[125I]hANP amount was expressed as percent of the
total radioactivity added to the incubation mixtures.
In a separated set of experiments big K-[125I]hANP
generated in PBS or PBS supplemented with HDL
was incubated at 37‡C for 24 h in plasma.
2.3. Gel chromatography
Samples containing big K-[125I]hANP were applied
to a 1.6U60 cm column of Sephacryl S-300 HR
(fractionation range, 10^1500 kDa). The column
was equilibrated at room temperature in PBS,
pH 7.0. The same bu¡er was used for the elution
step. The £ow rate was 30 ml/h; loading volumes
were 1 ml. Fractions (1 ml) were collected, directly
counted for 125I and the radioactive elution pro¢le
drawn. The recovery of radioactivity ranged from 80
to 90% of the total applied. The apparent molecular
size of the labeled material in the fractions was de-
termined by comparing its elution volume with that
of commercially available gel ¢ltration protein cali-
bration mixtures (protein size range, 25^669 kDa).
For this purpose, a plot of log molecular mass vs.
fraction number was constructed and the points
¢tted using curvilinear least-squares regression anal-
ysis. Big K-[125I]ANP, eluting in column fractions
34^40, 41^50, 51^60 and 61^75, included material
s 1500 kDa, 460^1100 kDa, 170^460 kDa and 40^
170 kDa in molecular size, respectively.
In order to accumulate su⁄cient amounts of en-
dogenous big ANP, 12 ml of pooled plasma either
native or incubated without K-[125I]hANP at 37‡C
for 24 h were consecutively chromatographed on Se-
phacryl S-300 HR column in 1 ml aliquots. Corre-
sponding fractions were pooled and stored at 320‡C.
According to the molecular mass ranges reported
above, fractions 34^40 (pool 1), 41^50 (pool 2), 51^
60 (pool 3) and 61^75 (pool 4) either from native or
incubated plasma were accumulated. Finally these
eight samples were dialyzed against ultrapure water,
lyophilized, and assayed for ANP, apolipoprotein
and lipid content.
2.4. Immunoreactive ANP (ir-ANP) analysis
The endogenous big ANP was measured by a com-
mercially available K-hANP RIA kit as previously
reported [22]. The values were reported as total
amount in each of the eight lyophilized samples.
2.5. Apolipoprotein and lipid analyses
Apo A-I and apo A-II were measured by radial
immunodi¡usion using commercially available kits.
Total cholesterol (T Chol), triglycerides (TG) and
phospholipids (PL) were measured by enzymatic col-
orimetry using commercially available Trinder-class
assays. For all kits we followed the manufacturer’s
instructions. The protocols were partially modi¢ed to
adapt suitable dilutions to our samples. All values
were reported as total amount in each of the eight
lyophilized samples.
2.6. Gel chromatography of commercial HDL
In order to characterize the commercial prepara-
tion of HDL, 1 ml of the solution (protein concen-
tration: 10 mg/ml) was applied to a Sephacryl S-300
HR column under identical conditions as described
in Section 2.3. The column was equilibrated and
eluted with PBS supplemented with 1 mM EDTA
(pH 7.0). Fractions of 1 ml were collected and moni-
tored for protein content by measurement of absor-
bance at 280 nm. The chromatographic pro¢le
showed that an initial small peak was eluted at the
void volume and was followed by a broader, larger-
sized peak. This latter ¢nding suggested a coalescing
of more peaks in one (Fig. 4A). In agreement with
the low lipid content, small HDL particles are de-
tected only in trace amounts in HDL fractions pre-
pared by density ultracentrifugation. Thus, the com-
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mercial preparation, in addition to medium HDL,
exhibited a modest degree of contamination by very
large and small HDL particles. On the basis of this,
fractions within the size ranges of s 1100 kDa (frac-
tions 31^40, pool a), 170^1100 kDa (fractions 41^60,
pool b), 56^170 kDa (fractions 61^72, pool c) and
26^56 kDa (fractions 73^80, pool d) were assembled.
2.7. Ligand blotting experiments
After concentration, the pools were immobilized in
nitrocellulose under vacuum. Membranes were satu-
rated with 5% skim milk in PBS for 1 h at room
temperature. After washing in PBS-0.05% Tween 20
(PBS-T), they were incubated for 5 h at 37‡C with
500 000 cpm K-[125I]hANP. Then the membranes
were extensively washed in PBS-T, dried and exposed
overnight at 370‡C to Kodak X-Omat AR autora-
diography ¢lm and a single intensifying screen.
3. Results
3.1. Characterization of big K-[125I]hANP
When big K-[125I]hANP, prepared in plasma, was
chromatographed on a Sephacryl S-300 HR column,
we invariably identi¢ed at least three peaks of labeled
material (Fig. 1A), in agreement with our previous
results [16]. A minor peak in the region of medium
HDL was unsteadily detected. The ¢rst peak (peak
I), representing the largest K-[125I]hANP containing
species, eluted at the void volume in fractions 34^40
(same position as dextran blue 2000); the second
peak (peak II), which eluted in fractions 41^50, in-
cluded big K-[125I]hANP of 460^1100 kDa and the
third peak (peak III), eluting in fractions 61^75, in-
cluded species 40^170 kDa in molecular size.
3.2. Incubation of K-[125I]hANP in plasma enriched
with lipoproteins
Mixtures of monomeric K-[125I]hANP and plasma
enriched with human HDL or VLDL or LDL were
incubated at 37‡C for 24 h. The Sephacryl S-300 HR
elution pro¢les of big K-[125I]hANP are shown in
Fig. 1. The presence of an excess of HDL in the
incubation mixture resulted in an evident decrease
Fig. 1. Representative gel ¢ltration pro¢les on Sephacryl S-300
HR of big K-[125I]hANP generated upon incubation at 37‡C for
24 h in plasma (A), in plasma supplemented with LDL (B),
with HDL (C), with VLDL (D), as described in detail in Sec-
tions 2.2 and 2.3. Big K-[125I]hANP elutes in three peaks: peak
I (fractions 34^40, s 1500 kDa), peak II (fractions 41^50, 460^
1100 kDa) and peak III (fractions 61^75, 40^170 kDa). Similar
pro¢les were obtained in three similar experiments.
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of peaks I and II and a signi¢cant increase of peak
III (Fig. 1C). When the experiment was repeated us-
ing VLDL essentially similar results were obtained
(Fig. 1D). Nevertheless a lower increase in big K-
[125I]hANP eluting in peak III was observed. Incuba-
tion for 24 h in the presence of LDL had no appre-
ciable e¡ect on the big K-[125I]hANP chromato-
graphic pro¢le (Fig. 1B).
3.3. Incubation of K-[125I]hANP in PBS in the
presence of lipoproteins
Mixtures of monomeric K-[125I]hANP and PBS
were incubated for 24 h at 37‡C with a physiological
concentration of human HDL or VLDL. The big K-
[125I]hANP formed was chromatographed on Se-
phacryl S-300 HR. On the basis of the results ob-
tained when the incubation was carried out in plas-
ma enriched with LDL (Fig. 1B), LDL were not
tested. Radioactive pro¢les are shown in Fig. 2. In
the control incubations, carried out in the absence of
lipoproteins (Fig. 2A), peak I was the only labeled
component eluting in the area of the V0. No modi¢-
cation of the big K-[125I]hANP pro¢le was observed
in the presence of VLDL (data not shown). On the
contrary, in the presence of HDL the elution pattern
(Fig. 2B) showed a shoulder in the descending limb
of peak I, corresponding to plasma peak II (Fig. 1A).
This shoulder was accompanied by a decrease in
peak I radioactivity. Thus, in PBS plus HDL the
plasma radioactive pro¢le was only partially re-
stored, since no radioactivity was recovered in the
region of peak III. Moreover, any attempt to gener-
ate peak III in bu¡er enriched with HDL, such as by
prolonged incubation for up to 5 days, was unsuc-
cessful (data not shown). Thus, it seems that peak III
material could be generated only in the presence of
plasma. Interestingly, when big ANP generated in
HDL-enriched PBS was incubated in plasma, peaks
I and II partially converted into peak III material
(Fig. 2C). On the contrary, incubation in plasma of
big ANP formed in PBS alone failed to generate
peak III (data not shown).
3.4. Chromatographic distribution of apolipoproteins
and lipids in native and incubated plasma
With regard to the nomenclature of plasma HDL
subclasses used, we will refer to a recent study [37]
which summarizes the knowledge about the chemical
composition and size of HDL species.
As shown in Fig. 3, the incubation of plasma
caused a change in the distribution of both apolipo-
proteins and lipids among the pools. Pool 1 (frac-
tions 34^40) did not contain detectable amounts of
apo A-I and apo A-II and likely consists of VLDL
Fig. 2. Representative gel ¢ltration pro¢les on Sephacryl S-300
HR of big K-[125I]hANP generated upon incubation at 37‡C for
24 h in PBS (A) and in PBS supplemented with HDL (B).
After a 24 h incubation at 37‡C of K-[125I]hANP in PBS sup-
plemented with HDL, big labeled ANP was separated by the
DCC method and incubated for 24 h at 37‡C in plasma (C), as
described in detail in Sections 2.2 and 2.3. Peak numbers are
the same described in Fig. 1. Analogous pro¢les were obtained
in a second experiment.
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Fig. 3. Distribution of apolipoproteins, lipids and ir-ANP in native plasma (left) and after 24 h incubation at 37‡C (right). Pools were
prepared as described in Section 2.3. All values are reported as the total amount in each pool.
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and LDL particles. This pool was enriched in lipids
following incubation. Apo A-I immunoreactivity be-
gan to appear in pool 2 (fractions 41^50). In this
pool, a slight increase in apo A-I, apo A-II and lipids
was observed following incubation. In this region,
very large HDL particles (large HDL) relatively
poor in apo A-I, apo A-II and lipids are supposed
to elute. Pool 3 (fractions 51^60) contained both
apolipoproteins A-I and A-II and lipids. Upon incu-
bation a decrease in both apolipoproteins and lipids
is observed in this region. Pool 4 (fractions 61^75),
containing the largest amount of apo A-I, was fur-
ther enriched in apo A-I and apo A-II contents upon
incubation, although apo A-II appeared to increase
at a smaller extent. The PL/apo A-I, T Chol/apo A-I,
TG/apo A-I and apo A-II/apo A-I molar ratios were
determined in order to identify the HDL subclasses.
The values reported in Fig. 3 indicate that pool 3
(fractions 51^60) likely contains typical spherical K-
migrating HDL particles (medium HDL), while
small pre-L-migrating HDL (small HDL) probably
elute in fractions 61^75 (pool 4). Indeed small
HDL are poorer in both apo A-II and lipid with
respect to the medium HDL. In particular, the PL/
apo A-I molar ratio in the small HDL is signi¢cantly
lower than that in the medium HDL (Table 1).
Moreover, the ¢rst ratio may be overestimated be-
cause plasma albumin, also eluting in the region of
small particles, is known to bind large quantities of
phospholipids.
In conclusion, the main result of plasma incuba-
tion was a marked decrease in medium HDL and a
striking increase in small HDL. A slight generation
of further large HDL was also observed.
3.5. Chromatographic distribution of ir-ANP in native
and incubated plasma
The ir-ANP was found in pools 2, 3 and 4 only,
both in native and incubated plasma (Fig. 3). No
ANP was detectable in pool 1, where apo A-I and
A-II were also absent. The major immunoreactivity
was present in native pool 3, in correspondence with
medium HDL. This region decreases in ir-ANP upon
incubation, apparently following the changes in dis-
tribution of apo A-I. A further relationship between
apo A-I and ANP distribution was found in the re-
gion of small HDL. In particular, this region was
enriched in both apo A-I and ir-ANP upon incuba-
tion.
3.6. Ligand binding of K-[125I]hANP to immobilized
HDL
Ligand binding studies were performed in the sam-
ples prepared following gel ¢ltration of commercial
HDL as described in Section 2.6. As showed in Fig.
4B, binding of K-[125I]hANP was observed mainly to
the small particle-rich pool and in decreasing order
to larger HDL species, and ¢nally no binding was
seen to the particles eluting at the void volume. As
can be seen by comparison of Fig. 4A,B, the signal
intensity was not related to the protein content.
These ¢ndings indicate that the HDL subspecies ex-
hibit di¡erent binding a⁄nity for K-[125I]hANP, in
agreement with that already observed for plasma
HDL. In fact, also under these conditions, the im-
mobilized small HDL particles bound K-[125I]hANP
with highest a⁄nity.
Table 1
Relationship between composition and molecular size of HDL particles
Pool Fraction
No.a
Molecular mass
(kDa)b
apo A-II/apo A-I PL/apo A-I T Chol/apo A-I TG/apo A-I HDL subclass
molar ratioc
3 51^60 460^170 N 0.33 56 71.1 15.7 medium
I 0.50 56 58 12
4 61^75 170^40 N 0.15 27.5 8.9 2.9 small
I 0.13 23.2 7.6 4.2
a;bSee Section 2.3.
cRatios were calculated using the values reported in Fig. 3 for native (N) and incubated (I) pooled plasma.
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4. Discussion
We have reported that di¡erent big forms of ANP
circulate in the plasma [16]. In fact upon gel ¢ltration
of human plasma on Sephacryl S-100 HR we ob-
tained, in addition to a major immunoreactive com-
ponent eluting in the V0 of the column, a second
peak representing material of approx. 67 kDa in mo-
lecular size. These same forms were generated by in
vitro incubation of K-[125I]ANP in plasma. Since only
material eluting in the V0 and no other form of big
labeled ANP was obtained in bu¡er, we interpreted
the former as aggregated ANP and the latter as ANP
bound to plasma components. Fractionation experi-
ments on Sephacryl S-300 HR showed that the bulk
of labeled big ANP was again excluded from this
more open gel (s 1500 kDa). We con¢rmed, by
seeding experiments with radiolabeled monomeric
peptide, that this big form consists of ANP aggre-
gates of amyloid or pre-amyloid nature since they
generate through a nucleation dependent mechanism.
Moreover, gel ¢ltration on Sephacryl S-300 HR re-
vealed that bound K-[125I]hANP comprises several
components of di¡erent molecular size, ranging
from 40 to 1100 kDa. This result indicates that
part of this bound material eluted from the Sephacryl
S-100 HR column together with the aggregated
forms. In the present paper, by using a Sephacryl
S-300 HR column, we demonstrate that the chroma-
tographic distribution of endogenous ANP corre-
sponds to the pro¢le of big K-[125I]hANP generated
in plasma, restrictedly to the bound ANP forms. In
fact, no immunoreactivity is recovered in the V0
where, on the contrary, the labeled aggregated ANP
is recovered. The lack of circulating ANP aggregates
agrees with the already demonstrated inability of en-
dogenous big ANP to act as a seed for polymeriza-
tion [16]. Thus we can state, thanks to the present
results, that endogenous big ANP consists only of
bound ANP.
We previously pointed [16] to a protecting role of
plasma binding factors against ANP ¢brillar poly-
merization that leads in vivo to IAA [1^3]. The novel
¢nding of the absence of circulating aggregates cor-
roborates this hypothesis and indicates that amyloid
preventing mechanisms are fully e¡ective at plasma
ANP concentrations. Although no direct information
about the nature of ANP binding factors could have
been drawn from that study [16], our preliminary
unpublished ¢ndings suggested a lipoprotein involve-
ment in human ANP biology.
In the present work we have tested whether lipo-
proteins were actually involved in the ANP binding
phenomenon. While no association between LDL
and K-[125I]hANP was found, the enrichment of plas-
ma with HDL or VLDL caused an increase of bound
ANP, suggesting that ANP associates with compo-
nents of HDL and VLDL. However, control experi-
ments in PBS showed no association of K-[125I]hANP
with VLDL. On the contrary, HDL addition to PBS
gave rise to iodinated ANP species eluting close to
the void volume only, likely as a consequence of
HDL aggregation in saline medium at 37‡C. In
fact, the chromatographic protein pro¢le of commer-
cial HDL incubated in PBS, in the absence of labeled
ANP, yielded only one peak which eluted at the void
volume (data not shown), di¡erently from non-incu-
bated HDL (Fig. 4A). Interestingly, aggregated HDL
Fig. 4. Representative protein pro¢le following gel ¢ltration
chromatography of commercial HDL (A). Autoradiography (B)
of pooled and concentrated fractions corresponding to molecu-
lar mass ranges of s 1100 kDa (fractions 31^40, pool a), 170^
1100 kDa (fractions 41^60, pool b), 56^170 kDa (fractions 61^
72, pool c) and 26^56 kDa (fractions 73^80, pool d). See Sec-
tions 2.6 and 2.7 for experimental details.
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bearing K-[125I]hANP, following incubation in plas-
ma, were partially converted into smaller species (40^
170 kDa), suggesting that the peak III material de-
rived from HDL remodeling. It is well known that
several plasma factors, including apoproteins, lipo-
lytic enzymes, transfer proteins and lipoproteins act-
ing as lipid acceptors [37^40], are responsible for the
remodeling and regulate levels and composition of
HDL subclasses. The remodeling hypothesis also
gives an explanation for the lack of quantitative cor-
relation between the decrease of peaks I and II and
the increase of peak III when HDL is added to plas-
ma. Particularly, the sequestering phenomenon of
monomeric ANP by newly generated small HDL
particles led to an unproportioned increase in peak
III radioactivity. In addition, the increase of peak III
when VLDL are added to the plasma now also
becomes clear. In fact, it has been demonstrated
that the lipoprotein lipase bound to VLDL may fa-
cilitate the action of the cholesteryl ester transfer
protein by improving the e⁄ciency of VLDL as cho-
lesterol acceptors [41] and thus the remodeling of
lipoproteins.
In an attempt to identify the HDL component
playing a role in ANP binding we examined the dis-
tribution of the protein and lipid constituents among
the chromatographic fractions from native and incu-
bated plasma. Just as we expected from plasma in-
cubation, lipid transfer from HDL to other lipopro-
teins and apolipoprotein redistribution were found.
In agreement with what already was reported [37],
these processes resulted mainly in the conversion of
medium into small HDL. Interestingly, immunoreac-
tive ANP followed the redistribution of apo A-I. In
fact, either ANP or apo A-I shifted in the region of
small HDL upon plasma incubation. On the basis of
this result, we hypothesize an association of ANP
and HDL via apo A-I as reported for AL [42] and
TTR [31].
In addition, we have found that the HDL sub-
classes display in vitro a di¡erent binding capacity
for ANP. In fact, the chromatographic pro¢le of
bound K-[125I]hANP formed in plasma showed that
radioactivity is mainly recovered in the fractions in-
cluding large and small particles of HDL, while only
sporadically a binding is observed in the medium
HDL region [16]. In contrast, following gel ¢ltration
of native plasma, endogenous ANP was also recov-
ered in this latter region. These results are only ap-
parently con£icting. In fact, a recent study [43] states
a conversion of small HDL in a unidirectional way
into medium or large HDL occurring in a compart-
ment outside the circulating plasma. On the basis of
these ¢ndings and of the lower binding capacity of
medium HDL for ANP, also evidenced by our ligand
blotting experiments, we suggest that in vivo small
HDL could combine with the hormone in plasma
and, following a conversion outside the circulating
compartment, return to the plasma pool as medium
particles loaded with ANP. In fact, under experimen-
tal conditions which do not allow remodeling, like in
the ligand blotting procedure, binding of ANP to
several HDL particles is observable. At the same
time, a maximal binding capacity of ANP was evi-
dent for HDL species with a low lipid/protein ratio,
thus justifying our major interest in small HDL.
On the basis of the amphipathic nature of both
apoproteins [44] and ANP [45], we hypothesize a
participation of hydrophobic forces in the interaction
of ANP with HDL, as postulated for AL [44]. Ac-
cording to the competitive binding between AL and
lipid to hydrophobic domains of apo E [46], we hy-
pothesize that the di¡erential binding to ANP of
small and medium HDL could be the result of the
exposure of a larger number of hydrophobic do-
mains in small HDL due to the partial delipidation
that occurs during the remodeling process.
Based on the knowledge that the amyloidogenic
protein concentration may be critical for the forma-
tion of amyloid [3], the biological importance of this
interaction might reside in the maintenance of low
levels of soluble ANP in biological £uids. In our
opinion these studies should be supportive to clinical
studies, since no treatment so far exists to speci¢cally
resolve the causes of amyloid deposits, while it is
clear that all interventions which reduce the supply
of the ¢bril protein precursors should be considered
[47].
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